Opportunity Information: Apply for RFA AG 22 012
The National Institutes of Health (NIH) announced this discretionary grant opportunity, RFA-AG-22-012, titled "High-Priority Behavioral and Social Research Networks in Alzheimers Disease and Alzheimers Disease-Related Dementias (R24 Clinical Trial Optional)." It uses the R24 research infrastructure mechanism and sits within the health funding category (CFDA 93.866). The basic intent is to build or strengthen collaborative networks and the supporting infrastructure needed to accelerate behavioral and social research focused on Alzheimers disease and Alzheimers disease-related dementias (AD/ADRD). A key theme is not simply funding isolated projects, but creating coordinated, network-based capacity that makes future studies easier to launch, more comparable across sites, and more useful for the broader research community.
This FOA emphasizes four major goals. First, it aims to develop new research and research infrastructure through networks devoted to behavioral and social science questions in AD/ADRD, which can include shared resources, coordinated methods, and cross-institution collaboration. Second, it explicitly seeks to attract new researchers into behavioral and social AD/ADRD research, meaning the networks are expected to lower barriers for entry, expand participation, and help cultivate investigators who may not traditionally work in dementia research. Third, it calls for a strong and intentional focus on health disparities, pushing applicants to build networks that can better study, understand, and ultimately reduce inequities in AD/ADRD risk, diagnosis, caregiving burden, access to services, and outcomes across different populations. Fourth, it targets persistent field-wide needs around harmonization and biomarker collection in large population panel studies, reflecting recommendations from the 2019 Behavioral and Social Research (BSR) National Advisory Council on Aging (NACA) review. In practical terms, this means NIH is encouraging networks to help align measures across studies (so results can be compared or combined) and to improve how biomarker data are collected or integrated within large, longitudinal, population-based panels that are especially valuable for tracking aging and dementia-related change over time.
The opportunity is labeled "Clinical Trial Optional," which generally signals that applicants may propose work that includes a clinical trial, but they are not required to do so. This is consistent with an infrastructure-building R24 approach where the core deliverable is often a functioning network, common protocols, shared measures, recruitment and engagement systems, and data and specimen strategies that can support multiple future research projects, some of which may involve trials.
Eligibility is broad and includes many types of U.S.-based organizations and governmental entities. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities and Indian housing authorities; tribal organizations that are not federally recognized; nonprofits with or without 501(c)(3) status (excluding institutions of higher education as a category distinction); for-profit organizations other than small businesses; and small businesses. The FOA also highlights additional eligible groups such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions. At the same time, it places clear limits on foreign involvement: non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations are not eligible to apply. However, foreign components, as defined by NIH policy, are allowed, meaning a U.S. applicant organization can include certain justified foreign collaborations or activities if they fit NIH rules.
Key administrative details provided include an original closing date of 2021-06-23 and a stated award ceiling of $250,000. The listing also notes that expected awards are not specified in the provided source data. Overall, this FOA is best understood as NIH investing in the connective tissue of the behavioral and social science AD/ADRD research ecosystem: building networks that expand the workforce, center health disparities, improve cross-study comparability, and strengthen biomarker and harmonization capabilities in large population-based research platforms, in line with the priorities outlined by the 2019 BSR NACA review.Apply for RFA AG 22 012
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "High-Priority Behavioral and Social Research Networks in Alzheimers Disease and Alzheimers Disease-Related Dementias (R24 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
- This funding opportunity was created on 2021-03-18.
- Applicants must submit their applications by 2021-06-23. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $250,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the official name and number of this NIH funding opportunity?
This discretionary grant opportunity is NIH FOA RFA-AG-22-012, titled "High-Priority Behavioral and Social Research Networks in Alzheimers Disease and Alzheimers Disease-Related Dementias (R24 Clinical Trial Optional)."
What type of grant mechanism does this FOA use?
The FOA uses the R24 research infrastructure mechanism, which is designed to support research infrastructure and coordinated capacity (such as networks, shared resources, and common approaches) rather than only funding isolated, single-site projects.
What funding category and CFDA number are associated with this opportunity?
The opportunity is listed under the health funding category and is associated with CFDA 93.866.
What is the main purpose of this grant opportunity?
The core intent is to build or strengthen collaborative networks and supporting infrastructure to accelerate behavioral and social research focused on Alzheimers disease and Alzheimers disease-related dementias (AD/ADRD). The emphasis is on creating coordinated, network-based capacity that helps future studies launch more easily, improves comparability across sites, and increases usefulness to the broader research community.
Is this FOA meant to fund individual research projects or something broader?
Based on the description provided, the FOA is not aimed at funding isolated projects. It prioritizes coordinated, network-based infrastructure, such as shared resources, coordinated methods, and cross-institution collaboration that can support multiple current and future research efforts.
What are the major goals NIH highlights for these networks?
The FOA emphasizes four major goals: (1) develop new research and research infrastructure through collaborative networks devoted to behavioral and social science questions in AD/ADRD; (2) attract new researchers into behavioral and social AD/ADRD research by lowering barriers to entry and cultivating investigators; (3) include a strong, intentional focus on health disparities to better study and reduce inequities in AD/ADRD; and (4) address field-wide needs related to harmonization and biomarker collection in large population panel studies, reflecting recommendations from the 2019 Behavioral and Social Research (BSR) National Advisory Council on Aging (NACA) review.
What does "Clinical Trial Optional" mean for this FOA?
"Clinical Trial Optional" indicates that applicants may propose work that includes a clinical trial, but a clinical trial is not required. This aligns with the R24 infrastructure focus, where deliverables often include a functioning network and shared systems that can support multiple future studies, some of which may involve trials.
What kinds of activities or deliverables are implied by an infrastructure-building R24 network?
From the provided description, the focus is on building the "connective tissue" for research, which can include common protocols, shared measures, recruitment and engagement systems, and data and specimen strategies to support multiple future research projects and improve cross-site comparability.
Why is harmonization emphasized in this FOA?
NIH is encouraging networks to align measures across studies so that results can be compared or combined more effectively. This emphasis is tied to persistent field-wide needs and recommendations referenced from the 2019 BSR NACA review.
What does the FOA say about biomarker collection in population panel studies?
The FOA targets needs around improving how biomarker data are collected or integrated within large, longitudinal, population-based panels. The intent is to strengthen these platforms, which are especially valuable for tracking aging and dementia-related change over time.
How does this opportunity address health disparities?
The FOA calls for a strong and intentional focus on health disparities. Applicants are encouraged to build networks that can better study, understand, and ultimately reduce inequities in AD/ADRD risk, diagnosis, caregiving burden, access to services, and outcomes across different populations.
Does the FOA aim to expand the AD/ADRD behavioral and social research workforce?
Yes. A stated goal is to attract new researchers into behavioral and social AD/ADRD research by lowering barriers to entry, expanding participation, and cultivating investigators who may not traditionally work in dementia research.
Who is eligible to apply?
Eligibility is broad and includes many types of U.S.-based organizations and governmental entities, including: state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities and Indian housing authorities; tribal organizations that are not federally recognized; nonprofits with or without 501(c)(3) status (with distinctions noted in the description); for-profit organizations other than small businesses; and small businesses.
Are specific institution types and community organizations explicitly highlighted as eligible?
Yes. The FOA highlights additional eligible groups such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions.
Can foreign (non-U.S.) organizations apply as the main applicant?
No. Non-domestic (non-U.S.) entities are not eligible to apply, according to the information provided.
Can a U.S. organization apply if it has a non-domestic component?
No. The description states that non-domestic components of U.S. organizations are not eligible to apply.
Are any types of foreign involvement allowed at all?
Yes. Foreign components, as defined by NIH policy, are allowed. This means a U.S. applicant organization may include certain foreign collaborations or activities if they are justified and comply with NIH rules.
What was the original closing date listed for this opportunity?
The listing provides an original closing date of 2021-06-23.
What is the stated award ceiling for this FOA?
The stated award ceiling in the provided information is $250,000.
How many awards are expected to be made?
The source data provided notes that expected awards are not specified.
What is the overall way to think about what NIH is investing in through this FOA?
Based on the description, NIH is investing in network infrastructure for the behavioral and social science AD/ADRD research ecosystem: building coordinated networks that expand the workforce, center health disparities, improve cross-study comparability through harmonization, and strengthen biomarker and harmonization capabilities within large population-based research platforms, consistent with priorities referenced from the 2019 BSR NACA review.
Browse more opportunities from the same category: Health
Next opportunity: Cooperative Agreement for CESU-affiliated Partner with Great Plains Cooperative Ecosystem Studies Unit
Previous opportunity: Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AG 22 012
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AG 22 012) also looked into and applied for these:
| Funding Opportunity |
|---|
| High-Priority Behavioral and Social Research Networks (R24 Clinical Trial Optional) Apply for RFA AG 22 013 Funding Number: RFA AG 22 013 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Research on Bat Immunology (R21 Clinical Trial Not Allowed) Apply for PAR 21 184 Funding Number: PAR 21 184 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R01 Clinical Trial Optional) Apply for PAR 21 175 Funding Number: PAR 21 175 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21 Clinical Trial Optional) Apply for PAR 21 176 Funding Number: PAR 21 176 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Core Centers for Clinical Research (CCCR) (P30)- Clinical Trial Not Allowed Apply for RFA AR 22 002 Funding Number: RFA AR 22 002 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Short Courses on Interdisciplinary Behavioral and Social Sciences Research on Alzheimer's Disease and Related Dementias (R25 - Clinical Trial Not Allowed) Apply for RFA AG 22 010 Funding Number: RFA AG 22 010 Agency: National Institutes of Health Category: Health Funding Amount: $139,000 |
| Short Courses on Interdisciplinary Behavioral and Social Sciences Research on Aging (R25 - Clinical Trial Not Allowed) Apply for RFA AG 22 009 Funding Number: RFA AG 22 009 Agency: National Institutes of Health Category: Health Funding Amount: $139,000 |
| Limited Competition: Alzheimers Disease Sequencing Project Follow-Up Study 2.0 (ADSP FUS 2.0): The Diverse Population Initiative (U01 Clinical Trial Not Allowed) Apply for PAR 21 212 Funding Number: PAR 21 212 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Neural Mechanisms of Force-Based Manipulations: High Priority Research Networks (U24 Clinical Trial Optional) Apply for RFA AT 21 006 Funding Number: RFA AT 21 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NHGRI Predoctoral to Postdoctoral Transition Award for a Diverse Genomics Workforce (F99/K00) Apply for PAR 21 143 Funding Number: PAR 21 143 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Transformative Research to Address Health Disparities and Advance Health Equity at Minority Serving Institutions (U01 Clinical Trial Allowed) Apply for RFA RM 21 022 Funding Number: RFA RM 21 022 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Transformative Research to Address Health Disparities and Advance Health Equity (U01 Clinical Trial Allowed) Apply for RFA RM 21 021 Funding Number: RFA RM 21 021 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R21 Clinical Trial Not Allowed) Apply for RFA HG 21 007 Funding Number: RFA HG 21 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mechanisms of HIV Resistance to Broadly Neutralizing Antibodies (bNAbs) (U01 Clinical Trial Not Allowed) Apply for RFA AI 21 009 Funding Number: RFA AI 21 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R01 Clinical Trial Not Allowed) Apply for RFA HG 21 006 Funding Number: RFA HG 21 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R43/R44) Apply for RFA HG 21 008 Funding Number: RFA HG 21 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding Post-Transcriptional Regulation of Intact and Defective HIV RNA (R61/R33 Clinical Trial Not Allowed) Apply for RFA AI 21 012 Funding Number: RFA AI 21 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD's Mentoring Networks to Enhance Clinician-Scientists' Participation in Research (R25 Clinical Trial Not Allowed) Apply for PAR 21 187 Funding Number: PAR 21 187 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Technology and Analytic Cores (TACs) and Research Management Unit (RMU) (UC2 Clinical Trial Not Allowed) Apply for RFA AR 21 016 Funding Number: RFA AR 21 016 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases: Disease Teams for Rheumatoid Arthritis, Lupus, Psoriatic Spectrum Diseases, and Sjgrens Syndrome (UC2 Clinical Trial Optional) Apply for RFA AR 21 015 Funding Number: RFA AR 21 015 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AG 22 012", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.